MeiraGTx Holdings plc

IPO

Next-Gen Genetic Medicine - MeiraGTx

Public · New York, United States · Founded 2015 · $220.0M raised

Headquarters
New York, New York
Employees
51–200
Founded
2015
Business Model
B2B
Total Funding
$220.0M
Last Round
$100.0M Corporate RoundApr 2026
Rounds
3
Type
Public

About

MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical-stage genetic medicines company with four late-stage clinical programs targeting the eye, Parkinson's disease, and xerostomia. The company uses innovative capsid, promoter, and translational control technologies to develop potent viral vectors, supported by end-to-end in-house GMP manufacturing. MeiraGTx has also developed a proprietary riboswitch platform enabling oral small molecule control of in vivo gene expression for metabolic and oncology applications.

Summary

MeiraGTx Holdings plc is a Biotech company based in New York, United States, founded in 2015. It has raised $220.0M in total across 3 rounds, most recently a $100.0M Corporate Round round in Apr 2026. Investors include Sanofi Ventures and UCL Technology Fund.

Tech & App Stack

5 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Corporate RoundCorporate RoundApr 2026
$100.0M

Sign up to see all 4 rounds

Series B through Corporate Round — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

MeiraGTx Holdings plc on Indexed.vc
<a href="https://indexed.vc/companies/meiragtx-holdings-plc"><img src="https://indexed.vc/api/badge/company/meiragtx-holdings-plc" alt="MeiraGTx Holdings plc on Indexed.vc" width="260" height="76" /></a>